AEON Biopharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$12.8M | $73.0M | — |
| Operating expenses | $12.8M | $73.0M | — |
| Cash from operations | -$17.3M | -$20.3M | — |
| Capital expenditure | $4,000 | — | — |
| Free cash flow | -$17.3M | — | — |
| Total assets | $5.6M | $3.1M | $6.8M |
| Total liabilities | $60.6M | $31.7M | $159.9M |
Shares outstanding 26.3M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.